Filing Flows

Filing Flows › DataMeds AI (MEDS) › How it makes money

How DataMeds AI (MEDS) makes money

DataMeds AI (MEDS) made $1.8M of revenue in the second quarter 2026 (Q2 2026), -77% from a year earlier. Pharmacy Retail Sales brought in $1.6M (89%); Third Party Logistics Services brought in $123K (7%); Product brought in $67K (4%).

Drawing the Sankey…

DataMeds AI revenue by segment, Q2 2026DataMeds AI revenue by segment, Q2 2026Pharmacy Retail Sales$1.6MThird Party Logistics Services$123KProduct$67K
DataMeds AI: revenue by line, Q1 2025 to Q2 2026DataMeds AI: revenue by line, Q1 2025 to Q2 2026ProductPharmacy Retail SalesThird Party Logistics…Product: $67K latestPharmacy Retail Sales: $1.6M latest$1.6MThird Party Logistics Services: $123K latestQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Product went from 98% of revenue in Q1 2025 to 4% in Q2 2026, the largest shift in the mix.
DataMeds AI revenue by quarterDataMeds AI revenue by quarter$12.4MQ4 2024$10.9MQ1 2025$7.8MQ2 2025$3.0MQ3 2025$1.7MQ4 2025$1.6MQ1 2026$1.8MQ2 2026

Revenue by segment, Q2 2026

SegmentRevenueShareQ/QY/Y
Pharmacy Retail Sales$1.6M89.4%—20×
Third Party Logistics Services$123K6.9%—-25%
Product$67K3.8%—-99%

Where each dollar of revenue goes

LineQ2 2026% of revenue
Revenue$1.8M100.0%

Revenue, quarter by quarter

QuarterRevenueY/Y
Q2 2026$1.8M-77%
Q1 2026$1.6M-86%
Q4 2025$1.7M-86%
Q3 2025$3.0M-47%
Q2 2025$7.8M175×
Q1 2025$10.9M—
Q4 2024$12.4M—

From DataMeds AI's 10-Q filed Aug 17, 2026 (on EDGAR).

Questions

How does DataMeds AI make money?

DataMeds AI (MEDS) made $1.8M of revenue in the second quarter 2026 (Q2 2026), -77% from a year earlier. Pharmacy Retail Sales brought in $1.6M (89%); Third Party Logistics Services brought in $123K (7%); Product brought in $67K (4%).

What is DataMeds AI's biggest business?

Pharmacy Retail Sales: $1.6M in the second quarter 2026, 89% of revenue, up 20-fold from a year earlier.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.